A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia

Abstract Introduction Sodium selenate increases tau dephosphorylation through protein phosphatase 2 activation. Here we report an open‐label Phase 1b study of sodium selenate as a disease‐modifying treatment for behavioral variant frontotemporal dementia (bvFTD). Methods Twelve participants with bvF...

Полное описание

Библиографические подробности

Главные авторы:	Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao‐Xin Li, Stuart McDonald, William T. O'Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis, Terence J. O'Brien
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2022-01-01
Серии:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Предметы:	anti‐tau treatment behavioral variant frontotemporal dementia (bvFTD) clinical trial fluid biomarkers frontotemporal lobar degeneration (FTLD) magnetic resonance imaging (MRI)
Online-ссылка:	https://doi.org/10.1002/trc2.12299
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!